Anti-inhibitor coagulant complex: Difference between revisions
No edit summary |
No edit summary |
||
| Line 16: | Line 16: | ||
human antihemophilic factor | human antihemophilic factor | ||
|indication= | |indication= | ||
| Line 28: | Line 27: | ||
|adverseReactions= | |adverseReactions= | ||
high antibody titer | high [[antibody]] titer | ||
<!--Black Box Warning--> | <!--Black Box Warning--> | ||
|blackBoxWarningTitle= | |blackBoxWarningTitle= | ||
WARNING | |||
|blackBoxWarningBody= | |blackBoxWarningBody= | ||
* | * Thrombotic and thromboembolic events have been reported during postmarketing surveillance following infusion of FEIBA VH or FEIBA NF, particularly following the administration of high doses and/or in patients with thrombotic risk factors. | ||
<!--Adult Indications and Dosage--> | <!--Adult Indications and Dosage--> | ||
Revision as of 00:37, 14 July 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gerald Chi
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Black Box Warning
|
WARNING
See full prescribing information for complete Boxed Warning.
* Thrombotic and thromboembolic events have been reported during postmarketing surveillance following infusion of FEIBA VH or FEIBA NF, particularly following the administration of high doses and/or in patients with thrombotic risk factors.
|
Overview
Anti-inhibitor coagulant complex is a human antihemophilic factor that is FDA approved for the {{{indicationType}}} of spontaneous bleeding episodes or in hemophilia A and hemophilia B patients with inhibitors. There is a Black Box Warning for this drug as shown here. Common adverse reactions include high antibody titer.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Condition1
- Dosing Information
- Dosage
Condition2
- Dosing Information
- Dosage
Condition3
- Dosing Information
- Dosage
Condition4
- Dosing Information
- Dosage
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
Condition1
- Developed by:
- Class of Recommendation:
- Strength of Evidence:
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of Anti-inhibitor coagulant complex in adult patients.
Non–Guideline-Supported Use
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Anti-inhibitor coagulant complex in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding FDA-Labeled Use of Anti-inhibitor coagulant complex in pediatric patients.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
Condition1
- Developed by:
- Class of Recommendation:
- Strength of Evidence:
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of Anti-inhibitor coagulant complex in pediatric patients.
Non–Guideline-Supported Use
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Anti-inhibitor coagulant complex in pediatric patients.
Contraindications
- Condition1
Warnings
|
WARNING
See full prescribing information for complete Boxed Warning.
* Thrombotic and thromboembolic events have been reported during postmarketing surveillance following infusion of FEIBA VH or FEIBA NF, particularly following the administration of high doses and/or in patients with thrombotic risk factors.
|
- Description
Precautions
- Description
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of Anti-inhibitor coagulant complex in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Anti-inhibitor coagulant complex in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
Drug Interactions
- Drug
- Description
Use in Specific Populations
Pregnancy
- Pregnancy Category
- Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Anti-inhibitor coagulant complex in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Anti-inhibitor coagulant complex during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Anti-inhibitor coagulant complex with respect to nursing mothers.
Pediatric Use
There is no FDA guidance on the use of Anti-inhibitor coagulant complex with respect to pediatric patients.
Geriatic Use
There is no FDA guidance on the use of Anti-inhibitor coagulant complex with respect to geriatric patients.
Gender
There is no FDA guidance on the use of Anti-inhibitor coagulant complex with respect to specific gender populations.
Race
There is no FDA guidance on the use of Anti-inhibitor coagulant complex with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Anti-inhibitor coagulant complex in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Anti-inhibitor coagulant complex in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Anti-inhibitor coagulant complex in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Anti-inhibitor coagulant complex in patients who are immunocompromised.
Administration and Monitoring
Administration
- Oral
- Intravenous
Monitoring
There is limited information regarding Monitoring of Anti-inhibitor coagulant complex in the drug label.
Condition1
- Description
IV Compatibility
There is limited information regarding IV Compatibility of Anti-inhibitor coagulant complex in the drug label.
Overdosage
Acute Overdose
Signs and Symptoms
- Description
Management
- Description
Chronic Overdose
There is limited information regarding Chronic Overdose of Anti-inhibitor coagulant complex in the drug label.
Pharmacology
There is limited information regarding Anti-inhibitor coagulant complex Pharmacology in the drug label.
Mechanism of Action
Structure
This image is provided by the National Library of Medicine.
Pharmacodynamics
There is limited information regarding Pharmacodynamics of Anti-inhibitor coagulant complex in the drug label.
Pharmacokinetics
There is limited information regarding Pharmacokinetics of Anti-inhibitor coagulant complex in the drug label.
Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of Anti-inhibitor coagulant complex in the drug label.
Clinical Studies
There is limited information regarding Clinical Studies of Anti-inhibitor coagulant complex in the drug label.
Condition1
- Description
How Supplied
Storage
There is limited information regarding Anti-inhibitor coagulant complex Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Anti-inhibitor coagulant complex |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Anti-inhibitor coagulant complex |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Patient Counseling Information of Anti-inhibitor coagulant complex in the drug label.
Precautions with Alcohol
- Alcohol-Anti-inhibitor coagulant complex interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
- Feiba NF®[1]
Look-Alike Drug Names
- N/A[2]
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
- ↑ "FEIBA NF (anti-inhibitor coagulant complex) kit".
- ↑ "http://www.ismp.org". External link in
|title=(help)
{{#subobject:
|Page Name=Anti-inhibitor coagulant complex |Pill Name=No image.jpg |Drug Name= |Pill Ingred=|+sep=; |Pill Imprint= |Pill Dosage= |Pill Color=|+sep=; |Pill Shape= |Pill Size (mm)= |Pill Scoring= |Pill Image= |Drug Author= |NDC=
}}
{{#subobject:
|Label Page=Anti-inhibitor coagulant complex |Label Name=Anti-inhibitor coagulant complex11.png
}}
{{#subobject:
|Label Page=Anti-inhibitor coagulant complex |Label Name=Anti-inhibitor coagulant complex11.png
}}